NDAINTRATRACHEALSUSPENSION
Approved
Mar 2012
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SURFAXIN (lucinactant) is a synthetic pulmonary surfactant suspension administered intratracheally to treat respiratory distress syndrome (RDS) in premature infants. It replaces deficient endogenous surfactant to reduce surface tension in the lungs and improve gas exchange. The drug represents a fully synthetic alternative to animal-derived surfactants in neonatal critical care.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30%), indicating a stable but challenged commercial environment with ongoing market defense initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SURFAXIN currently shows zero linked job postings, indicating limited active hiring on the brand or a mature team structure. Career opportunities likely involve specialized neonatal/NICU market expertise and defending market share against established competitors in a consolidated segment.
Brand ManagerRegional Sales Manager
Worked on SURFAXIN at Lee's Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.